IFNL3 and hepatitis A virus infection: This pharmacogenetic substudy shows that the IL28B rs8099917 polymorphism is associated with SVR to hepatitis C therapy in HCV-HIV co-infected patients and therefore confirms the results that have been reported in many other studies performed in HCV mono-infected [9]–[13] and in HCV-HIV co-infected patients [14]–[17].